Tinea Capitis Treatment in Children
Oral systemic antifungal therapy is mandatory for tinea capitis—topical therapy alone is insufficient and should never be used as monotherapy. 1
First-Line Treatment Selection: Species-Directed Approach
The critical decision point is identifying (or presuming based on local epidemiology) the causative organism, as treatment efficacy varies dramatically by species 1:
For Trichophyton Species (T. tonsurans, T. violaceum, T. soudanense):
Terbinafine is the preferred agent due to superior efficacy and shorter treatment duration 1:
- < 20 kg: 62.5 mg daily for 2-4 weeks
- 20-40 kg: 125 mg daily for 2-4 weeks
- > 40 kg: 250 mg daily for 2-4 weeks
For Microsporum Species (M. canis, M. audouinii):
Griseofulvin is the preferred agent 1:
- < 50 kg: 15-20 mg/kg/day (can increase to 25 mg/kg/day if needed) for 6-8 weeks
- > 50 kg: 1 g daily for 6-8 weeks
- Take with fatty food to enhance absorption
Key mechanistic insight: Terbinafine fails in Microsporum infections because it cannot be incorporated into prepubertal children's hair shafts and is not excreted in sweat/sebum, preventing it from reaching the scalp surface where Microsporum arthroconidia reside 1. This explains cure rates of only 67.9% for Trichophyton vs 88.5% for Microsporum with griseofulvin 1.
When to Initiate Treatment
Start treatment immediately without awaiting culture results when any of these cardinal signs are present 1:
- Kerion formation
- Scalp scaling with alopecia
- Cervical/occipital lymphadenopathy
- Black dot pattern
Culture results take 2-4 weeks, and delaying treatment increases transmission risk and potential for scarring 1.
Diagnostic Sampling
Obtain scalp samples via hairbrush, toothbrush, cotton swab, or hair pluck for microscopy and culture 1. The hairbrush method is most efficient and least invasive 2. Do not wait for results to treat if clinical suspicion is high.
Treatment Failure Management
If no clinical improvement after standard duration 1:
- First, assess: compliance, drug absorption, reinfection from untreated contacts
- If clinical improvement but positive mycology: Continue current therapy 2-4 weeks longer
- If no improvement: Switch to second-line therapy
Second-Line Options:
Itraconazole (effective against both Trichophyton and Microsporum) 1:
- 5 mg/kg/day for 2-4 weeks, OR
- 50-100 mg daily for 4 weeks
Alternative strategy: If itraconazole was first-line, switch to terbinafine for Trichophyton or griseofulvin for Microsporum 1.
Critical Adjunctive Measures
Family Screening (Essential for T. tonsurans):
Screen and treat all household members and close contacts 1. Over 50% of family members may harbor occult infection, and failure to treat contacts results in high recurrence rates 1.
Topical Adjuncts to Reduce Transmission:
Use antifungal shampoos (ketoconazole 2%, selenium sulfide 1%, or povidone-iodine) to decrease spore shedding 1. These do NOT replace systemic therapy but reduce transmission.
School Attendance:
Children on appropriate systemic therapy should attend school/nursery—exclusion is unnecessary 1.
Monitoring and Treatment Endpoint
The endpoint is mycological cure, not clinical improvement 1. Repeat mycology sampling monthly until clearance is documented 1. Clinical improvement without mycological cure predicts relapse.
Common Pitfalls to Avoid
- Using topical therapy alone: Guarantees treatment failure 1
- Wrong drug for wrong species: Terbinafine for Microsporum or inadequate griseofulvin duration for Trichophyton
- Inadequate dosing: Griseofulvin underdosing (< 15 mg/kg/day) is common and ineffective
- Stopping at clinical cure: Must confirm mycological clearance
- Ignoring household contacts: Leads to reinfection cycles with T. tonsurans 1
- Not taking griseofulvin with fatty food: Reduces bioavailability significantly
Licensing Considerations
In the UK, griseofulvin remains the only licensed treatment for tinea capitis in children, though terbinafine is widely used off-label and recommended in guidelines 1. Itraconazole is not licensed for children ≤12 years in the UK for this indication 1.
Safety Profile
Both griseofulvin and terbinafine are well-tolerated: GI disturbances and rashes occur in <8% of children, with only 0.8% requiring discontinuation 1. Routine liver monitoring is not required for standard treatment courses, though baseline and follow-up testing may be prudent for prolonged therapy (>8 weeks) 3.